 Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapsedrefractory Acute Lymphoblastic Leukemia expected in Q4 of 2022. With positive results, a Biologics Licensing Application of obe-cel for the treatment of patients with rr B-cell ALL is expected by end of 2023. 